Loading...
Loading...
Gabelli raises its rating on AngioDynamics
ANGO to Hold as the company announces accretive deal to acquire Navilyst Medical for $372 million in cash and stock.
Gabelli comments, "Overall we think this is a strategic and accretive deal for ANGO. This deal also more than offsets the loss of the LC Bead distribution agreement and does not preclude the company from future tuck-ins to improve the product line. We are upgrading our recommendation to a HOLD now that we are gaining additional visibility into the company's future."
ANGO closed at $12.96 a share on Tuesday.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in